JX-594

BIOLOGICAL5 trials

Sponsors

Jennerex Biotherapeutics, Samsung Medical Center, Andrea McCart

Conditions

CRCCarcinoma, HepatocellularColorectal CarcinomaMelanomaOvarian Cancer

Phase 1

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

CompletedNCT00429312

Jennerex BiotherapeuticsMelanoma

Start: 2007-02-01End: 2009-12-01Updated: 2026-07-27

Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

CompletedNCT01394939

Jennerex BiotherapeuticsColorectal Carcinoma, CRC

Start: 2012-01-01End: 2015-10-01Updated: 2026-08-05

A Trial of JX-594 in Refractory Colorectal Carcinoma

CompletedNCT01469611

Samsung Medical CenterColorectal Carcinoma

Start: 2010-07-31End: 2015-01-31Updated: 2017-02-17

Phase 2

A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma

CompletedNCT01171651

Jennerex BiotherapeuticsCarcinoma, Hepatocellular

Start: 2009-05-26End: 2012-09-27Updated: 2026-07-14

Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin

WithdrawnNCT02017678

Andrea McCartOvarian Cancer

Start: 2014-01-31End: 2015-06-30Updated: 2014-09-17